Multiple Sclerosis Journal - October 2017 - 1449

N Dubuisson, F Puentes et al.
21. Semra YK, Seidi OA and Sharief MK. Heightened
intrathecal release of axonal cytoskeletal proteins
in multiple sclerosis is associated with progressive
disease and clinical disability. J Neuroimmunol 2002;
122(1-2): 132-139.
22. Madeddu R, Farace C, Tolu P, et al. Cytoskeletal
proteins in the cerebrospinal fluid as biomarker of
multiple sclerosis. Neurol Sci 2012; 34(2): 181-186.
23. Theotokis P, Lourbopoulos A, Touloumi O, et al.
Time course and spatial profile of Nogo-A expression
in experimental autoimmune encephalomyelitis in
C57BL/6 mice. J Neuropathol Exp Neurol 2012;
71(10): 907-920.
24. Reindl M, Khantane S, Ehling R, et al. Serum and
cerebrospinal fluid antibodies to Nogo-A in patients
with multiple sclerosis and acute neurological
disorders. J Neuroimmunol 2003; 145(1-2): 139-147.
25. Jurewicz A, Matysiak M, Raine CS, et al. Soluble
Nogo-A, an inhibitor of axonal regeneration, as a
biomarker for multiple sclerosis. Neurology 2007;
68(4): 283-287.
26. Selmaj K, Jurewicz A, Matysiak M, et al. Soluble
Nogo-A in CSF is not a useful biomarker for multiple
sclerosis. Neurology 2009; 72(19): 1708-1709.
27. Proescholdt MA, Jacobson S, Tresser N, et al.
Vascular endothelial growth factor is expressed
in multiple sclerosis plaques and can induce
inflammatory lesions in experimental allergic
encephalomyelitis rats. J Neuropathol Exp Neurol
2002; 61(10): 914-925.
28. Stanojlovic M, Pang X, Lin Y, et al. Inhibition
of vascular endothelial growth factor receptor 2
exacerbates loss of lower motor neurons and axons
during experimental autoimmune encephalomyelitis.
PLoS ONE 2016; 11(7): e0160158.
29. Rasol HAA, Helmy H, El-Mously S, et al. Vascular
endothelial growth factor-A mRNA gene expression
in clinical phases of multiple sclerosis. Ann Clin
Biochem 2016; 53(Pt. 2): 252-258.
30. Theoharides TC and Konstantinidou AD.
Corticotropin-releasing hormone and the blood-brainbarrier. Front Biosci 2007; 12: 1615-1628.
31. Ribatti D, Iaffaldano P, Marinaccio C, et al. First
evidence of in vivo pro-angiogenic activity of
cerebrospinal fluid samples from multiple sclerosis
patients. Clin Exp Med 2016; 16(1): 103-107.
32. Iacobaeus E, Amoudruz P, Ström M, et al. The
expression of VEGF-A is down regulated in
peripheral blood mononuclear cells of patients with
secondary progressive multiple sclerosis. PLoS ONE
2011; 6(5): e19138.
33. Al-Chalabi A and Miller CCJ. Neurofilaments
and neurological disease. Bioessays 2003; 25(4):
346-355.
journals.sagepub.com/home/msj

34. Lee MK and Cleveland DW. Neuronal intermediate
filaments. Annu Rev Neurosci 1996; 19(1): 187-217.
35. Petzold A. Neurofilament phosphoforms: Surrogate
markers for axonal injury, degeneration and loss.
J Neurol Sci 2005; 233(1-2): 183-198.
36. Teunissen CE and Khalil M. Neurofilaments as
biomarkers in multiple sclerosis. Mult Scler 2012;
18(5): 552-556.
37. Norgren N, Rosengren L and Stigbrand T. Elevated
neurofilament levels in neurological diseases. Brain
Res 2003; 987(1): 25-31.
38. Petzold A, Keir G, Green AJE, et al. A specific
ELISA for measuring neurofilament heavy chain
phosphoforms. J Immunol Methods 2003; 278(1-2):
179-190.
39. Burman J, Zetterberg H, Fransson M, et al. Assessing
tissue damage in multiple sclerosis: A biomarker
approach. Acta Neurol Scand 2014; 130(2): 81-89.
40. Novakova L, Axelsson M, Khademi M, et al.
Cerebrospinal fluid biomarkers as a measure of
disease activity and treatment efficacy in relapsingremitting multiple sclerosis. J Neurochem 2017; 141:
296-304.
41. Villar LM, Picón C, Costa-Frossard L, et al.
Cerebrospinal fluid immunological biomarkers
associated with axonal damage in multiple sclerosis.
Eur J Neurol 2015; 22(8): 1169-1175.
42. Malmestrom C, Haghighi S, Rosengren L, et al.
Neurofilament light protein and glial fibrillary acidic
protein as biological markers in MS. Neurology 2003;
61(12): 1720-1725.
43. Teunissen CE, Iacobaeus E, Khademi M, et al.
Combination of CSF N-acetylaspartate and
neurofilaments in multiple sclerosis. Neurology 2009;
72(15): 1322-1329.
44. Trentini A, Comabella M, Tintoré M, et al.
N-acetylaspartate and neurofilaments as biomarkers
of axonal damage in patients with progressive
forms of multiple sclerosis. J Neurol 2014; 261(12):
2338-2343.
45. Romme Christensen J, Börnsen L, Khademi M, et al.
CSF inflammation and axonal damage are increased
and correlate in progressive multiple sclerosis. Mult
Scler 2013; 19(7): 877-884.
46. Lim ET, Grant D, Pashenkov M, et al. Cerebrospinal
fluid levels of brain specific proteins in optic neuritis.
Mult Scler 2004; 10(3): 261-265.
47. Gunnarsson M, Malmeström C, Axelsson M, et al.
Axonal damage in relapsing multiple sclerosis is
markedly reduced by natalizumab. Ann Neurol 2011;
69(1): 83-89.
48. Kuhle J, Leppert D, Petzold A, et al. Neurofilament
heavy chain in CSF correlates with relapses and
1449
https://journals.sagepub.com/home/msj
Table of Contents for the Digital Edition of Multiple Sclerosis Journal - October 2017
